Raymond H. Diradoorian - 08 Jul 2024 Form 4 Insider Report for LIFECORE BIOMEDICAL, INC. \DE\ (LFCR)

Reporting relationship: Director
Issuer ticker: LFCR
Reported as of: 08 Jul 2024
Net transaction value: $0
SEC form: 4
Accepted by SEC: 10 Jul 2024, 19:49:30 UTC
Prior SEC filing: 02 Feb 2024
Source filing: View source filing
Reporting owner signature: /s/ Rebecca Hilt, Attorney-In-Fact for Raymond Diradoorian

Filing notes and source

Key filing fact

Raymond H. Diradoorian filed Form 4 for LIFECORE BIOMEDICAL, INC. \DE\ (LFCR) on 10 Jul 2024.

Key facts

This page summarizes Raymond H. Diradoorian's Form 4 filing for LIFECORE BIOMEDICAL, INC. \DE\ (LFCR).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 10 Jul 2024, 19:49.

Change

Previous filing in this sequence was filed on 02 Feb 2024.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

LFCR transaction

Common Stock

Award

Transaction value
Shares: +30,000
Change %: +75%
Price
Shares after: 69,978
Date: 08 Jul 2024
Ownership: Direct
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

The restricted stock units convert into common stock of Lifecore Biomedical, Inc. on a 1 for 1 basis.

Footnote F2

Vests on earlier of the first anniversary of the grant date or the date of the annual meeting of stockholders first held in calendar year 2025, subject to potential acceleration.